Background Lipodystrophy is common in HIV-infected patients receiving protease inhibitors
(PIs), stavudine, and zidovudine. Adipocytokines may be altered in lipodystrophy. We …

Objective The aim of the study was to evaluate the evolution of plasma adipokines and
lipodystrophy in protease inhibitor‐naïve vertically HIV‐infected children on highly active …

Alterations of fat distribution and insulin resistance are associated with increased risk of
metabolic derangements and cardiovascular disease. HIV-infected adult patients on …

Objective: To assess the rate of progression of lipodystrophy and the associated metabolic
disturbances over a 2-year period in children and to assess risk factors associated with …

Objective To achieve a better understand of the pathophysiology of HIV-related lipoatrophy,
we compared the mRNA expression of adipocytokines in fat samples from patients and …

HIV-1-infected patients on antiretroviral therapy frequently develop a lipodystrophy
syndrome, characterized by peripheral lipoatrophy and visceral fat redistribution associated …

Highly active antiretroviral therapy might lead to the development of dyslipidemia and
lipodystrophy (LD) syndrome. We carried out a multicenter prospective study of 22 human …

Lipodystrophy can be avoided by selecting therapies with benign effects on adipose tissue.
Switching from certain HIV protease inhibitors may normalize the metabolic profile fairly …

Background Abnormal levels of tumour necrosis factor (TNF)-α, interleukin (IL)-6 and
adiponectin have been observed in HIV patients with lipodystrophy. However, because …

OBJECTIVE: Few studies have thus far assessed body composition by dual energy X-ray
absorptrometry (DXA) in children with HIV, primarily because reference data for normally …